A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated, Aggressive B-cell Lymphoma
Latest Information Update: 26 Jul 2024
At a glance
- Drugs Golcadomide (Primary) ; Iberdomide (Primary) ; Polatuzumab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Prednisone; Rituximab; Rituximab; Vincristine
- Indications B-cell lymphoma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 23 Jul 2024 Planned primary completion date changed from 10 Jun 2024 to 31 Jul 2024.
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results (n=78) assessing combined results from the GOLCA dose escalation and expansion phases, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.